Table 2. Association between lung immune prognostic index (LIPI) and survival.
| Variables | Univariate | Multivariate | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Overall survival | |||||
| Age (≥75 vs. <75 years) | 1.02 (0.44–2.34) | 0.97 | 1.75 (0.57–5.37) | 0.33 | |
| Sex (male vs. female) | 0.65 (0.40–1.08) | 0.10 | 1.00 (0.48–2.07) | 1.00 | |
| ECOG-PS (2 vs. 1 vs. 0) | 3.13 (1.63–6.04) | 0.0007* | 3.33 (1.43–7.73) | 0.005* | |
| Smoking (former vs. current vs. never) | 0.85 (0.61–1.20) | 0.36 | 0.76 (0.47–1.23) | 0.27 | |
| Histology (squamous vs. nonsquamous) | 0.80 (0.49–1.31) | 0.37 | 0.68 (0.35–1.33) | 0.26 | |
| TNM stage at diagnosis (IV vs. III) | 1.40 (0.83–2.35) | 0.21 | 1.30 (0.67–2.54) | 0.44 | |
| Brain metastases (yes vs. no) | 2.41 (1.47–3.96) | 0.0005* | 1.77 (0.96–3.29) | 0.07 | |
| Prior lines of therapy (1 vs. 2 vs. 3 vs. 4 vs. 5) | 0.99 (0.80–1.23) | 0.91 | 0.93 (0.71–1.24) | 0.64 | |
| dNLR (>3 vs. ≤3) | 2.80 (1.56–5.01) | 0.0006* | 0.69 (0.27–1.75) | 0.44 | |
| LDH (> ULN vs. ≤ ULN) | 1.00 (1.00–1.01) | 0.0007* | 1.00 (1.00–1.00) | 0.018* | |
| LIPI (poor vs. intermediate vs. good) | 3.12 (2.12–4.60) | <0.0001* | 3.67 (1.96–6.86) | <0.0001* | |
| Progression-free survival | |||||
| Age (≥75 vs. <75 years) | 0.58 (0.26–1.32) | 0.20 | 0.70 (0.27–1.78) | 0.45 | |
| Sex (male vs. female) | 0.60 (0.38–0.91) | 0.02* | 0.80 (0.46–1.39) | 0.42 | |
| ECOG-PS (2 vs. 1 vs. 0) | 1.61 (0.93–2.76) | 0.09 | 1.65 (0.92–2.96) | 0.10 | |
| Smoking (former vs. current vs. never) | 0.82 (0.62–1.10) | 0.19 | 0.90 (0.63–1.28) | 0.57 | |
| Histology (squamous vs. nonsquamous) | 0.78 (0.52–1.18) | 0.24 | 0.73 (0.43–1.23) | 0.24 | |
| TNM stage at diagnosis (IV vs. III) | 1.35 (0.88–2.07) | 0.18 | 1.63 (1.00–2.68) | 0.05 | |
| Brain metastases (yes vs. no) | 2.00 (1.26–3.04) | 0.003* | 1.54 (0.91–2.59) | 0.11 | |
| Prior lines of therapy (1 vs. 2 vs. 3 vs. 4 vs. 5) | 1.12 (0.94–1.34) | 0.20 | 1.07 (0.88–1.31) | 0.48 | |
| dNLR (>3 vs. ≤3) | 1.25 (0.73–2.16) | 0.42 | 0.75 (0.35–1.64) | 0.48 | |
| LDH (> ULN vs. ≤ ULN) | 1.00 (0.99–1.00) | 0.80 | 1.00 (0.99–1.00) | 0.99 | |
| LIPI (poor vs. intermediate vs. good) | 1.45 (1.05–2.03) | 0.03* | 1.49 (0.94–2.38) | 0.09 | |
HR, hazard ratio; CI, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; dNLR, derived neutrophil to lymphocyte ratio; LDH, lactate dehydrogenase; ULN, upper limit of normal. *, P<0.05 indicates statistically significant.